Clinical Research Directory
Browse clinical research sites, groups, and studies.
Decision Impact Trial of KidneyIntelX
Sponsor: Renalytix AI, Inc.
Summary
The current trial is designed to evaluate how the results of KidneyIntelX test impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
Official title: A Prospective Decision Impact Trial of KidneyIntelX in Patients With Type 2 Diabetes and Existing Chronic Kidney Disease
Key Details
Gender
All
Age Range
23 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1500
Start Date
2021-11-01
Completion Date
2024-12-01
Last Updated
2024-04-12
Healthy Volunteers
No
Conditions
Interventions
KidneyIntelX
KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
Locations (1)
Delmar Family Medicine
Slingerlands, New York, United States